Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
Top Cited Papers
- 17 July 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (3) , 257-262
- https://doi.org/10.1161/01.cir.104.3.257
Abstract
Background Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and obesity; however, it is not known whether they increase risk of atherosc...Keywords
This publication has 12 references indexed in Scilit:
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest painThe American Journal of Cardiology, 2000
- Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility.Heart, 1995
- The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary VasomotionNew England Journal of Medicine, 1995
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992